Decoding molecular signatures and identifying therapeutic targets in triple-negative breast cancer subtypes using...

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype resistant to standard therapies.
• TNBC's heterogeneity presents significant challenges for effective patient management.
• Current treatment strategies often rely on chemotherapy, highlighting the need for novel therapeutic targets.

Purpose of the Study:

• To identify key transcription factors (TFs) regulating cancer pathways in TNBC subtypes.
• To discover subtype-specific marker genes and their associated TFs.
• To evaluate molecular characteristics for improved TNBC management and personalized treatment.

Main Methods:

• Utilized a multi-omics approach, focusing on transcriptomic data analysis.
• Compared TNBC subtype-specific cell lines with normal breast epithelial cell lines.
• Identified common cancer-related genes, analyzed their alteration patterns, and linked them to driver mutations within subtypes.

Main Results:

• Identified a common set of genes involved in cancer-related pathways across TNBC subtypes.
• Found specific genes (ERBB3, ERBB4, HLA-B, AKT1, GNAS, FGFR4, PIK3R3, AXIN2) to be primary risk factors.
• These genes exhibit differential expression and alteration patterns, correlating with survivability and subtype.

Conclusions:

• The identified genes (ERBB3, ERBB4, AKT1, etc.) are potential subtype-specific biomarkers for TNBC.
• These molecular markers are crucial for understanding TNBC heterogeneity.
• Findings pave the way for developing personalized anticancer treatment strategies for TNBC patients.